Kevin Kunzmann

How physicians in a shrinking field have taken on a greater burden of leadership roles in patient care.

How does psychiatry access differ among patients, and how should it become individualized?

Following the ground-breaking LEAP findings in 2015, and updated clinical guidelines in 2017, there's a noted disparity of adherence among pediatric clinics.

Investigative drug DB102 will be assessed in approximately 200 patients with newly diagnosed glioblastoma in a Denovo-led phase 2b trial.

A new study shows adult e-cigarette use in the US was steadily dropping since 2014— before spiking in 2018 among adults aged 18-24 years.

The new indication marks the sixth for treatment in venous thromboembolism with the direct oral anti-coagulant.

New findings from the 12-week pivotal JADE MONO-1 trial show the JAK1 inhibitor's benefit in skin clearance and itch relief.

The oral therapy showed benefit in reducing symptoms and migraine-related pain, as well as aura, within 2 hours of administration.

The data presented at the EADV Congress in Madrid builds on the findings reported at 52 and 64 weeks in the phase 3 reSURFACE 1 and 2 trials.

The CDC Influenza Division medical director reported new findings at IDWeek showing older patients with influenza subtype A were more likely to be hospitalized.

New findings show nearly 2000 children in the US were hospitalized due to a gun-related ocular injury from 2008-2014. Most patients faced uncertain visual status going forward.

The fully active robot and accompanying preparation software provides surgeons capability to individualize strategy pre-operation.

New findings presented at IDWeek show vaccinated children have inconsistent protection from the A(H3N2) flu subtype.

How a community-based assessment can show physicians the ways in which the flu spreads.

New 12-week findings from a head-to-head phase 4 trial showed the Eli Lilly product's benefit for plaque psoriasis clearance.

The CDC Influenza Division medical officer discusses findings from their pediatric assessment at IDWeek.

A new phase 2b trial shows the investigative therapy significantly improves the rate of patients with hives control over 12 weeks versus its competitor.

African Americans are more greatly burdened by the cardiovascular condition and its common comorbidities. Are new therapies able to help?

How has testing and diagnosis changed?

The indication makes it the first respiratory biologic available either at home or in a professional setting, with eight-week maintenance dosing.

Trelegy Ellipta could become the first triple-combination, single-inhaler therapy approved for the treatment of both asthma and COPD.

New phase 2b data shows the JAK1 inhibitor is beneficial for moderate to severe adult atopic dermatitis.

How new agents, improved study outcomes, and priority on diagnosis has bettered the state of dermatologic care.

Its approval was based on findings from the limited assessment of pediatric patients in PANORAMA-HF, showing reduction of a cardiovascular biomarker.

An expert with the American Lung Association will lead discussion on one of the greatest drivers of death in the US.

The investigative ICS/LAMA/LABA inhaler therapy reported positive findings from its phase 3 ETHOS trial in August, though the results were not included in the FDA application.

The 12-year update highlights promising novel therapy classes, and sets disparities between pediatric and adult chronic cough treatment.

From immunotherapy to biologics, the field of allergy pharmacotherapy is looking promising.

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.